Skip to main content

Peer Review reports

From: Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)

Original Submission
23 Feb 2023 Submitted Original manuscript
19 Mar 2023 Author responded Author comments - Hongfeng Gou
15 Jun 2023 Reviewed Reviewer Report
17 Jun 2023 Reviewed Reviewer Report - Yasuyuki Kawamoto
22 Jun 2023 Author responded Author comments - Hongfeng Gou
Resubmission - Version 2
19 Mar 2023 Submitted Manuscript version 2
12 Jul 2023 Reviewed Reviewer Report
16 Jul 2023 Reviewed Reviewer Report - Yasuyuki Kawamoto
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
18 Jul 2023 Editorially accepted
7 Aug 2023 Article published 10.1186/s12885-023-11188-4

You can find further information about peer review here.

Back to article page